Authors: Sharon Salt, Editor
Abstracts presented at the Alzheimer’s Association International Conference (14–18 July 2019, Los Angeles, CA, USA) have illustrated various advances in in the field of blood biomarkers for Alzheimer’s disease and other dementias. This includes approaches for measuring abnormal versions of amyloid in the blood and correlating it wish established Alzheimer’s markers, and new methods for assessing α-synuclein in blood.
“These new testing technologies, which are currently under development by industry and academic researchers, could also potentially be used to track the impact of therapies in clinical trials,” explained Maria Carrillo, Chief Science Officer at the Alzheimer’s Association (IL, USA).
Is plasma amyloid an informative biomarker for Alzheimer’s disease?
In January 2018, Akinori Nakamura (National Center for Geriatrics and Gerontology, Obu, Japan) and colleagues described the potential of a blood-based biomarker for amyloid-β that might identify individuals who are likely to develop Alzheimer’s dementia in the future. They measured plasma levels of amyloid-related peptides and generated the biomarker by combining peptide ratios (e.g., Aβ1-40/Aβ1-42).
At AAIC, the researchers provided results of a study that aimed to analyze the plasma biomarkers in comparison to brain amyloid PET scans, structural MRI, FDG-PET and behavioral tests.